Core Viewpoint - A lawsuit has been filed against MoonLake Immunotherapeutics and its senior executives for potential violations of federal securities laws, following disappointing results from its Phase 3 clinical trials for sonelokimab [1][2][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Southern District of New York, with investors having until December 15, 2025, to seek lead plaintiff status [2]. - The complaint alleges violations under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in MoonLake common stock [2]. Group 2: Company Background - MoonLake Immunotherapeutics is a clinical-stage biotechnology company focused on developing therapies for inflammatory diseases, particularly through its investigational drug sonelokimab [3]. - The company claimed that its "strong clinical data" from the Phase 2 MIRA trial indicated a superior clinical response for patients compared to competitors [4]. Group 3: Clinical Trial Results - The VELA Phase 3 trials for sonelokimab reported disappointing results, with VELA-2 failing to meet its primary endpoint, raising concerns about the drug's regulatory approval and commercial viability [5][6]. - Following the announcement of the trial results on September 28, 2025, MoonLake's stock price plummeted nearly 90%, from $61.99 per share to $6.24 per share [6].

Core Viewpoint - Beyond Meat, Inc. is under investigation for potential violations of federal securities laws, particularly concerning the inflation of the value of certain long-lived assets [1][3]. Financial Performance and Stock Movement - On October 24, 2025, Beyond Meat announced an expected non-cash impairment charge for the three months ended September 27, 2025, related to certain long-lived assets, which was anticipated to be material. This announcement led to a significant stock price drop of approximately 23%, from $2.84 per share on October 23, 2025, to $2.185 per share on October 24, 2025 [4]. - Following this, on November 3, 2025, the company delayed its earnings announcement for Q3 2025 due to the need for additional time to complete the impairment review, resulting in further declines in the stock price during trading on that day [5]. Company Operations and Asset Management - In late 2023, Beyond Meat conducted a global operations review and depreciated certain long-lived assets, stating that these assets were recorded at the lower of their carrying value or fair value less costs to sell, with no impairments reported [2].

Core Viewpoint - A class action lawsuit has been filed against James Hardie Industries plc and certain senior executives for securities fraud following a significant stock drop due to potential violations of federal securities laws [1][3]. Company Overview - James Hardie Industries is a producer and marketer of high-performance fiber cement building solutions, primarily used in external siding for the residential building industry in the U.S. and Canada [4]. Allegations and Stock Performance - The lawsuit claims that James Hardie misrepresented the strength and momentum of its North American fiber cement segment, asserting that sales were driven by sustainable customer demand rather than inventory loading by channel partners [5]. - On August 19, 2025, James Hardie disclosed a 12% decline in North American fiber cement sales, attributed to destocking efforts by customers, leading to a stock price drop of over 34%, from $28.43 to $18.64 per share [6]. Legal Proceedings - Investors have until December 23, 2025, to request to lead the case in the U.S. District Court for the Northern District of Illinois, with the case titled Laborers' District Council and Contractors' Pension Fund of Ohio v. James Hardie Industries plc, et al. [3]. Management Changes - On November 17, 2025, it was announced that Rachel Wilson would step down from her role as CFO of James Hardie [7].

Core Viewpoint - CarMax, Inc. is facing a class action lawsuit for securities fraud following a significant drop in stock price attributed to alleged violations of federal securities laws [1][3]. Group 1: Lawsuit Details - The lawsuit has been filed against CarMax and certain senior executives, with claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [3]. - Investors have until January 2, 2026, to request to lead the case in the U.S. District Court for the District of Maryland [3]. Group 2: Financial Performance - CarMax reported disappointing financial results for Q2 of fiscal year 2026, including a 5.4% decline in retail used unit sales, a 6.3% decline in comparable store used unit sales, and a 2.2% decline in wholesale units [6]. - The net income for Q2 was approximately $95.4 million, down from $132.8 million in the previous year [6]. Group 3: Stock Price Impact - Following the financial results announcement on September 25, 2025, CarMax's stock price dropped by $11.45 per share, or roughly 20%, from $57.05 to $45.60 [7]. - The unexpected departure of CEO Bill Nash on November 6, 2025, and a weak preliminary Q3 outlook led to an additional stock price drop of over 24% [7]. Group 4: Market Context - CarMax had previously promoted strong demand for its vehicles, which was allegedly inflated by a temporary surge in purchases before U.S. tariffs were imposed [4]. - The company attributed the sales declines to a "pull forward" in demand due to the tariff announcement [6].

SAN FRANCISCO, Nov. 21, 2025 (GLOBE NEWSWIRE) -- On November 7, 2025, The Wall Street Journal reported that Senate Democrats are demanding information related to Fiserv, Inc.’s (NYSE: FI) former CEO and Chairman Frank Bisignano after the company said that it wouldn’t reach financial forecasts set by its former boss. The lawmakers reportedly are seeking information about “Bisignano’s role in developing and approving [Fiserv’s] financial forecasts, his focus on short-term initiatives within the company and an ...

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Sanara MedTech Inc. ("Sanara†or the "Company†) (NASDAQ: SMTI) investors concerning the Company's possible violations of the federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON SANARA MEDTECH INC. (SMTI), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS. What Happened? On Novem. ...

Nov 20, 2025 4:07 PM Eastern Standard Time Deadline Soon: Fortinet, Inc. (FTNT) Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit Share LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz reminds investors of the upcoming November 21, 2025 deadline to participate as a lead plaintiff in the securities fraud class action lawsuit filed on behalf of investors who acquired Fortinet, Inc. ("Fortinet†or the "Company†) (NASDAQ: FTNT) common sto ...

BREAKING: BFA Law Notifies James Hardie Industries plc Investors of CFO Departure and Reminds Investors to Contact the Firm about the Securities Class ActionNovember 20, 2025 3:46 PM EST | Source: Bleichmar Fonti & AuldNew York, New York--(Newsfile Corp. - November 20, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against James Hardie Industries plc (NYSE: JHX) and certain of the Company's senior executives for securities fr ...

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Paysafe Limited ("Paysafe†or the "Company†) (NYSE: PSFE) investors concerning the Company's possible violations of the federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON PAYSAFE LIMITED (PSFE), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS. What Happened? On November 13, 2. ...

RADNOR, Pa., Nov. 20, 2025 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that an amended securities class action lawsuit has been filed against CarMax, Inc. (“CarMax”) (NYSE: KMX) which expands the class period to include those who purchased or otherwise acquired CarMax securities between June 20, 2025, and November 5, 2025, inclusive (the “Class Period”). The lead plaintiff deadline is January 2, 2026. CONTACT KESSLER TOPAZ MELTZER & CHECK, LLP: If ...